

Deletion of the Virion Host Shut-off Gene Enhances Neuronal-Selective Transgene Expression from an HSV Vector Lacking Functional IE Genes

Yoshitaka Miyagawa,^{1,6} Gianluca Verlengia,^{2,3} Bonnie Reinhart,¹ Fang Han,^{1,4} Hiroaki Uchida,^{1,5} Silvia Zucchini,² William F. Goins,¹ Michele Simonato,^{2,3} Justus B. Cohen,¹ and Joseph C. Glorioso¹

¹Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, PA 15219, USA; ²Department of Medical Sciences, University of Ferrara, Ferrara 44121, Italy; ³Division of Neuroscience, University Vita-Salute San Raffaele, 20132 Milan, Italy; ⁴School of Pharmaceutical Sciences, Tsinghua University, Beijing 100084, China; ⁵Division of Bioengineering, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan

The ability of herpes simplex virus (HSV) to establish lifelong latency in neurons suggests that HSV-derived vectors hold promise for gene delivery to the nervous system. However, vector toxicity and transgene silencing have created significant barriers to vector applications to the brain. Recently, we described a vector defective for all immediate-early gene expression and deleted for the joint region between the two unique genome segments that proved capable of extended transgene expression in non-neuronal cells. Sustained expression required the proximity of boundary elements from the latency locus. As confirmed here, we have also found that a transgene cassette introduced into the ICP4 locus is highly active in neurons but silent in primary fibroblasts. Remarkably, we observed that removal of the virion host shutoff (*vhs*) gene further improved transgene expression in neurons without inducing expression of viral genes. In rat hippocampus, the *vhs*-deleted vector showed robust transgene expression exclusively in neurons for at least 1 month without evidence of toxicity or inflammation. This HSV vector design holds promise for gene delivery to the brain, including durable expression of large or complex transgene cassettes.

INTRODUCTION

Replication-defective herpes simplex virus (HSV)-based vectors have the potential to provide an invaluable tool to both studies of brain function and treatment of CNS disorders. HSV genomes persisting in neurons do not integrate and can serve as a platform for therapeutic gene expression. Replication-defective HSV vectors have been tested for gene therapy approaches in the CNS¹⁻³ and peripheral nervous system.⁴⁻⁷ However, CNS applications have been plagued by residual neuronal toxicity and progressive loss of transgene expression.⁸⁻¹⁰ Viral toxicity results from expression of the viral immediate early (IE) protein ICP0, a protein with functions related to viral chromatin modification and resistance to innate anti-viral responses.¹¹ In the absence of ICP0, rapid genome silencing ensues, resulting in low transgene expression, while, in the presence of ICP0, significant toxicity results in loss of neuronal cell function and viability.

In sensory neurons, ICP0 fails to accumulate in the nucleus,¹² and ICP0-mediated cytotoxicity is further avoided by silencing of the viral genome and the establishment of latency. The viral latency-associated transcript (LAT) locus remains transcriptionally active during latency, and the LAT promoter elements have been used to express transgenes in sensory neurons.^{4,5,13,14} However, expression was typically short-term or low,^{4,15} and promoter activity was not seen in all latently infected neurons.¹⁶ We have recently reported that, in the absence of IE gene activity, transgene expression from a non-viral promoter can be maintained in non-neuronal cells when the expression cassette is placed between two clusters of CTCF binding motifs referred to as CTRL1 and CTRL2¹⁷ flanking the LAT promoter.¹⁸ This arrangement remained active when relocated to different intergenic regions unrelated to the latency locus. Interestingly, primary neurons isolated from fetal rat dorsal root ganglia (rDRG) also displayed expression of a second reporter cassette located in the deleted ICP4 locus. This finding prompted further examination of the ability of the ICP4 locus to support transgene expression in neurons in the brain.

Preliminary observations in our lab suggested that elimination of the virion host shut-off function (*vhs*) may further reduce the already minimal toxicity of IE gene-depleted vectors. *Vhs* functions as a virulence factor that reduces immune recognition of infected cells in vivo and helps evade the innate anti-viral interferon (IFN) responses;¹⁹⁻²¹ *vhs*-deficient viruses are attenuated for neurovirulence. Since *vhs* is an mRNA-specific RNase, we reasoned that it could potentially reduce transgene mRNA and corresponding protein expression. Thus we

Received 1 December 2016; accepted 13 June 2017;
<http://dx.doi.org/10.1016/j.omtm.2017.06.001>.

⁶Present address: Department of Biochemistry and Molecular Biology, Nippon Medical School, Tokyo 113-8602, Japan

Correspondence: Joseph C. Glorioso, Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, 428 Bridgeside Point 2, 450 Technology Drive, Pittsburgh, PA 15219, USA.

E-mail: gloriosoc@pitt.edu




Figure 1. Structure and Analysis of the JΔNI8 Vector

(A) Genomic structure of KOS-37 BAC and the derivative JΔNI5 and JΔNI8 vectors loxP-flanked (BAC regions between U_L37 and U_L38 not shown). U_L, unique long segment; U_S, unique short segment. The terminal and internal inverted repeats are represented by open boxes. Deletions in JΔNI5¹⁸ and JΔNI8 are indicated by black boxes (Δ). Both vectors contain the entry-enhancing N/T mutations in the gB gene (gB:NT)⁴⁵ and a ubiquitin C promoter (UbCp)-mCherry cassette in the ICP4 locus; the SV40 poly(A) region of the mCherry cassette is represented by a small patterned box. The cross-hatched horizontal box (βICP22) indicates conversion of the ICP22 IE gene to early-expression kinetics by promoter TAATGARAT deletion. (B) Growth curves of JΔNI5 and JΔNI8 in complementing cells. U2OS-ICP4/27 cells were infected with JΔNI5 and JΔNI8 vectors at 1 gc/cell, and supernatant virus titers were determined in gc per milliliter every day for 5 days (averages of duplicate wells). (C) Relative nuclear viral DNA levels at 2 hr post-infection of HDFs with 5,000 gc of JΔNI5 and JΔNI8. Viral gc numbers were determined by qPCR for the gD gene normalized to the cellular 18S rRNA gene content (averages of duplicate wells). (D) mCherry protein and (E) mRNA expression in vector-infected HDFs without and with ICP0 complementation. Cells were infected at 25,000 gc/cell with JΔNI5ΔB or JΔNI8ΔB and superinfected 6 days later with mock or QOZHG vector (10⁸ gc/well). One day later, microscopy fields were imaged for mCherry fluorescence, DAPI-stained nuclei, and bright field. Separately, mRNA was collected 1 day after superinfection, and mCherry mRNA levels in duplicate samples were measured in triplicate, averaged, and normalized to viral gc in the same samples. Normalized values ±SD are presented relative to JΔNI5ΔB infected cells at 7 dpi.

transgenes that are too large for accommodation by other vector systems.

RESULTS

Vector Construction and Characterization in Non-complementing Fibroblasts

JΔNI8 was derived from JΔNI5 by deletion of the *vhs* locus (Figure 1A). JΔNI5 and JΔNI8

grew at comparable rates on ICP4- and ICP27-complementing U2OS cells [U2OS-ICP4/27]¹⁸ (Figure 1B), showing that *vhs* did not clearly contribute to virus yield in cultured cells. Infection of human dermal fibroblasts (HDFs) with JΔNI5 and JΔNI8 at 5,000 genome copies (gc)/cell resulted in comparable levels of viral DNA in the nuclei of infected cells at 2 hr post-infection (hpi) (Figure 1C), indicating that deletion of *vhs* did not alter virus entry or transport of viral DNA into the nucleus.

We previously demonstrated that removal of bacterial artificial chromosome (BAC) sequences from BAC-based viral vectors reduces vector toxicity for non-complementing cells.¹⁸ Cre recombination was used to remove the bacterial sequences from JΔNI5 and

deleted the *vhs* (U_L41) gene from our most recent vector, JΔNI5,¹⁸ generating a new backbone that was named JΔNI8, and compared the 2 vectors for transgene expression from the deleted ICP4 locus in rat brain.

The results of our analyses show that the human ubiquitin C (UbC) promoter placed between the end points of the ICP4 gene deletion allows expression of the linked reporter gene in vivo in rat hippocampal neurons. Furthermore, expression was enhanced by deletion of the *vhs* gene. No vector-associated toxicity was observed following rat brain injections and expression persisted in neurons of the CNS for at least 1 month, providing an effective platform for the delivery of therapeutic transgenes to the CNS, including multiple transgenes or




Figure 2. JΔNI5ΔB and JΔNI8ΔB Transgene Expression in HDFs and rDRGs

(A) mCherry transgene expression in rDRG cultures. Cells were infected with 3,000 gc/cell of JΔNI5ΔB (top) or JΔNI8ΔB (bottom). Bright-field (left) and mCherry fluorescence images (right) were taken at 7 (left panels) and 14 dpi (right panels). (B) mCherry mRNA levels in JΔNI5ΔB- and JΔNI8ΔB-infected rDRGs at 7 and 14 dpi. mCherry mRNA levels were normalized to viral gc in the same samples, and the normalized values are presented relative to JΔNI5ΔB-infected cells at 7 dpi. (C) Cytotoxicity for rDRGs in culture. Cells were infected with KOS, JΔNI5ΔB, or JΔNI8ΔB virus at 3,000 gc/cell or mock-infected, and cell viability was measured in triplicate by MTT assay at 5 dpi. Plotted values represent the mean ratios of virus-infected to mock-infected cells. (D) Transgene and viral gene expression in HDFs (left) and rDRGs (right). HDF and rDRG cultures were infected with JΔNI5ΔB or JΔNI8ΔB vectors at 25,000 gc/cell or 3,000 gc/cell, respectively. At 7 dpi, mRNA levels of selected genes were measured by qRT-PCR analysis. Data conversion was performed using JΔNI5 BAC DNA standard curves generated with the same gene-specific primers and normalization to viral gc in each sample. Values are presented relative to JΔNI5ΔB-infected HDF at 7 dpi. Data in (B) and (D) represent averages ±SD of two independent experiments.

vhs deletion caused a decrease in mCherry mRNA levels (~6-fold), these levels were extremely low compared to those in the presence of ICP0 (Figure 1E).

Characterization of Gene Expression in Neuronal Cells

We previously reported that mCherry expression from JΔNI5-based vectors was markedly higher in rDRG neurons than in fibroblasts in vitro at 3 dpi. We therefore infected rDRG cultures with JΔNI5ΔB and JΔNI8ΔB to assess the effect of *vhs* deletion on transgene expression in these cells. At 7 and 14 dpi, rDRGs infected with either virus showed

JΔNI8, creating JΔNI5ΔB and JΔNI8ΔB, respectively. Following transduction of HDFs with JΔNI5ΔB and JΔNI8ΔB, neither vector showed noticeable mCherry transgene expression at 7 dpi (Figure 1D), consistent with our previous results for JΔNI5.¹⁸ The presence of viral DNA in the nuclei of infected HDFs (Figure 1C) with little corresponding protein expression suggested that both viral genomes were epigenetically silenced. Restoration of the IE gene ICP0 to ICP0-deficient vectors has been shown to counteract epigenetic repression.^{22,23} As anticipated, when JΔNI5ΔB- and JΔNI8ΔB-infected HDFs were superinfected with QOZHG virus¹² to supply ICP0 expression, mCherry expression was restored (Figures 1D and 1E). While the qRT-PCR data (Figure 1E) suggested that the

abundant mCherry fluorescence, but the signals were stronger in JΔNI8ΔB- than in JΔNI5ΔB-infected cultures (Figures 2A and S1). Analysis of reverse transcribed mRNA by qPCR revealed that mCherry gene expression in JΔNI8ΔB-infected rDRGs was approximately 2.5- and 3-fold higher than in JΔNI5ΔB-infected rDRGs at 7 and 14 dpi, respectively (Figure 2B). To eliminate the possibility that mCherry expression was affected by cytotoxicity, we assessed cell viability after transduction of rDRGs with JΔNI5ΔB or JΔNI8ΔB. No difference in cell viability was observed between vector- and mock-infected cells, indicating that neither vector displayed noticeable cytotoxicity (Figure 2C). Together, these results showed that in neuronal cells, both JΔNI5 and




Figure 3. GFP Expression from J Δ NI7GFP Δ B and J Δ NI8GFP Δ B in Infected HDFs and DRGs

(A) Schematic diagram of the genomic structure of the J Δ NI8GFP Δ B vector derived from J Δ NI7GFP¹⁸ by deletion of the *vhs* (*U_L41*) gene. Like J Δ NI7GFP, J Δ NI8GFP contains a CAG promoter-eGFP expression cassette in the LAT intron between an enhancer-like LAT region (LAP2 or LATP2)^{4,46,47} and CTRL2. (B) GFP fluorescence and (C) relative GFP mRNA levels in J Δ NI7GFP Δ B- and J Δ NI8GFP Δ B-infected HDFs (25,000 gc/cell) at 7 and 14 dpi. GFP qRT-PCR data were normalized to viral gc in the same samples and are presented as expression relative to that in J Δ NI7GFP Δ B infected cells at 7 dpi. (D) GFP fluorescence and (E) relative GFP mRNA levels in J Δ NI7GFP Δ B- and J Δ NI8GFP Δ B-infected rDRGs (3,000 gc/cell) at 7 and 14 dpi. Data in (C) and (E) represent averages \pm SD of two independent experiments.

notable exceptions. mCherry expression per genome copy was 50- to 100-fold higher than in HDFs, considerably higher than expression of any of the viral genes, and approximately 2-fold higher from J Δ NI8 Δ B than from J Δ NI5 Δ B (Figure 2D, right side). Of interest, the expression of ICP34.5 in DRGs, while similar between the two vectors, was also elevated compared to HDFs (\sim 25-fold for J Δ NI8 Δ B, \sim 17-fold for J Δ NI5 Δ B). The ICP34.5 gene ($\gamma_{134.5}$) and the mCherry transgene are both located in a terminal repeat, relatively close to one another in the circular genome. The kinetically modified promoter of the ICP22 gene is also located in a terminal repeat in our J Δ NI viruses and ICP22 was expressed more abundantly than the majority of viral genes in J Δ NI5 Δ B-infected DRGs. However, this was not seen in J Δ NI8 Δ B-infected DRGs. Together, these results indicated that the *vhs* deletion caused selective upregulation of mCherry expression in a cell-restricted manner without considerable changes in the global pattern of HSV gene expression.

J Δ NI8 can mediate prolonged transgene expression from the UbC promoter at the ICP4 locus without apparent cytotoxicity and that increased transgene expression correlates with the *vhs* gene deletion in J Δ NI8.

To determine whether the *vhs* gene influences global viral gene expression, we measured the mRNA levels of the mCherry transgene and selected viral genes representing different kinetic classes and regions of the viral genome in both HDFs and rDRGs (Figure 2D). In HDFs, expression of most viral genes from J Δ NI5 Δ B and J Δ NI8 Δ B was comparable, regardless of kinetic class or genomic location, indicating that removal of *vhs* did not dramatically alter viral gene expression (Figure 2D, left side). In DRGs, expression of individual genes was also similar between J Δ NI5 Δ B and J Δ NI8 Δ B, but with a few

notable exceptions. mCherry expression per genome copy was 50- to 100-fold higher than in HDFs, considerably higher than expression of any of the viral genes, and approximately 2-fold higher from J Δ NI8 Δ B than from J Δ NI5 Δ B (Figure 2D, right side). Of interest, the expression of ICP34.5 in DRGs, while similar between the two vectors, was also elevated compared to HDFs (\sim 25-fold for J Δ NI8 Δ B, \sim 17-fold for J Δ NI5 Δ B). The ICP34.5 gene ($\gamma_{134.5}$) and the mCherry transgene are both located in a terminal repeat, relatively close to one another in the circular genome. The kinetically modified promoter of the ICP22 gene is also located in a terminal repeat in our J Δ NI viruses and ICP22 was expressed more abundantly than the majority of viral genes in J Δ NI5 Δ B-infected DRGs. However, this was not seen in J Δ NI8 Δ B-infected DRGs. Together, these results indicated that the *vhs* deletion caused selective upregulation of mCherry expression in a cell-restricted manner without considerable changes in the global pattern of HSV gene expression.

Transgene Expression from the LAT Region in Neuronal and Non-neuronal Cells

We recently reported that GFP transgene expression from the CAG promoter (CMV immediate-early enhancer/chicken β -actin promoter/chimeric intron) was maintained in non-neuronal cells when the expression cassette was placed between two clusters of CTCF binding motifs flanking the LAT promoter in J Δ NI5; this vector was referred to as J Δ NI7GFP.¹⁸ We deleted the *vhs* gene from J Δ NI7GFP, creating J Δ NI8GFP (Figure 3A), to assess the effect on GFP expression. HDFs and rDRGs were infected with BAC-deleted (Δ) J Δ NI7GFP or J Δ NI8GFP, GFP fluorescence from infected cells

was visualized at 7 and 14 dpi, and GFP mRNA levels were measured in the same cells. In HDFs, GFP fluorescence in J Δ NI7GFP Δ B-infected cells was higher at both time points than in J Δ NI8GFP Δ B-infected cells (Figure 3B), and mRNA levels were approximately 3-fold higher in J Δ NI7GFP Δ B- than in J Δ NI8GFP Δ B-infected cells at both 7 and 14 dpi, decreasing by \sim 25% (J Δ NI7GFP Δ B) and \sim 35% (J Δ NI8GFP Δ B) between the two time points (Figure 3C). In contrast, GFP fluorescence in rDRGs was higher at 7 and 14 days post-infection with J Δ NI8GFP Δ B than with J Δ NI7GFP Δ B (Figure 3D), and GFP mRNA abundance was 2.5-fold higher in J Δ NI8GFP Δ B- than in J Δ NI7GFP Δ B-infected cultures at 7 dpi, although a difference was no longer observed at 14 dpi (Figure 3E). While the increase in GFP expression in rDRGs caused by the *vhs* deletion was thus transient compared to the increase in mCherry expression in rDRGs noted earlier, these results indicated that the *vhs* deletion promoted transgene expression in neuronal cells independent of the promoter or location of the expression cassette within the viral genome. We confirmed that the disruption of the LAT locus and insertion of the GFP cassette did not noticeably alter the effect of the *vhs* deletion on mCherry expression (Figure S2). The reduced expression of GFP observed in HDFs highlights the cell-type dependence of the effect of *vhs* removal on transgene expression.

Analysis of the J Δ NI8 Δ B Vector in Neurons In Vivo

To determine whether our vectors were capable of non-cytotoxic transgene expression in neuronal cells in vivo, we injected J Δ NI5 Δ B and J Δ NI8 Δ B into rat hippocampus. We used J Δ NI5R0 Δ B, an ICP0-rescued derivative of J Δ NI5 (Figure S3), as a positive control for mCherry expression and vector-associated toxicity. At 7 days post-vector administration, J Δ NI5 Δ B showed relatively low mCherry expression and normal neuronal morphology (Figure 4B) that were maintained at 1 month (Figure 4E). In comparison, more robust mCherry expression was observed in J Δ NI5R0 Δ B-injected animals at 7 days (Figure 4A), but a significant loss of mCherry signal was observed after 1 month, and the morphology of the mCherry positive cells indicated substantial cytotoxicity (Figure 4D). J Δ NI8 Δ B-injected animals displayed enhanced mCherry expression in the hippocampus at 7 days compared to J Δ NI5 Δ B (Figure 4C), and only a modest reduction in mCherry signal was apparent at 1 month without overt change in cell morphology (Figure 4F); as opposed to J Δ NI5R0 Δ B-injected hippocampi, cells in J Δ NI8 Δ B-injected hippocampi maintained a clear neuronal morphology with many dendritic and axonal elongations. We confirmed that J Δ NI8 Δ B transgene expression was restricted to neurons by double-label immunofluorescence for mCherry and markers of neurons (Nissl), astrocytes (GFAP), and oligodendrocytes (O4) (Figure S4). Quantification of mCherry expression in the hippocampus (Figure 4G) demonstrated that, in J Δ NI5 Δ B-injected animals, only approximately 2% of the pixels were mCherry positive at both time points, whereas some 12% were positive in J Δ NI8 Δ B-injected animals at 7 days with only a modest reduction to approximately 7% by 1 month. The J Δ NI5R0 Δ B injection yielded about 15% mCherry positive pixels at 7 days, but this fell to less than 2% by 1 month. Both the loss of mCherry positive cells and the changes in cell morphology in the


J Δ NI5R0 Δ B-injected animals were consistent with vector cytotoxicity that was not observed in animals injected with either of the ICP0-deficient vectors.

To further assess toxicity in rat brain, Fluoro-Jade C staining was performed on brain sections at 7 days post-vector administration. Fluoro-Jade C stains degenerating neurons, regardless of the cause of degeneration, and provides a clear indication of cytotoxicity. In J Δ NI5R0 Δ B-injected animals, many green, Fluoro-Jade C-positive cells were observed, whereas no signal was detected in either J Δ NI5 Δ B- or J Δ NI8 Δ B-injected animals (Figures 5A–5C). We also examined the expression of CD45 as a marker for the accumulation of inflammatory cells in the injected area. Many CD45 positive cells accumulated near the mCherry positive cells in J Δ NI5R0 Δ B-injected animals, while only a few CD45 positive cells were observed in either J Δ NI5 Δ B- or J Δ NI8 Δ B-injected animals (Figures 5D–5F). Similarly, both caspase-3, an apoptotic marker (Figures 5G–5I), and NOS-2, an inducible nitric oxide synthase involved in the immune response (Figures 5J–5L), were induced by J Δ NI5R0 Δ B injection, but not by either J Δ NI5 Δ B or J Δ NI8 Δ B injection. Quantification of these data is shown in Figure 5M. Taken together, these observations confirmed that the presence of ICP0 results in neuronal cytotoxicity and apoptosis in the hippocampus, along with activation of inflammatory cell recruitment. Deletion of ICP0 reduced these negative consequences although transgene expression was also reduced. Importantly, removal of the *vhs* gene from the ICP0-deficient vector resulted in enhanced transgene expression in the hippocampus without toxicity.

DISCUSSION

HSV vectors offer the distinct advantage that they can accommodate large payloads; for example, our current replication-defective backbones offer approximately 30 kb of usable space. This makes HSV an ideal vector for gene therapy requiring the expression of large or multiple transgenes. Given HSV's ability to enter and establish latency in sensory ganglia, current gene therapy studies using HSV have focused on the peripheral nervous system, treating conditions such as chronic pain and neuropathy.²⁴ Establishing a platform for replication-defective gene delivery to the CNS has been hampered by problems including early silencing of CMV-promoter driven transgenes and limited, low-level transgene expression from other promoters such as the viral latency promoter.^{2,9} The level of transgene expression is intricately tied to expression of the viral ICP0 protein: while ICP0 increases transgene expression, it also increases cytotoxicity.²⁵

We recently generated an ICP0-deficient vector, J Δ NI5, that is nontoxic and allowed transgene expression from an ectopic promoter in multiple non-neuronal cell lines and rDRGs in vitro when the transgene cassette was inserted between CTRLs associated with the viral latency locus. Consistent with an overall silencing of expression from the viral genome, a UbC-promoter-driven second transgene present in the deleted ICP4 locus was not expressed in non-neuronal cells. Surprisingly, however, it was expressed in DRGs. This







Figure 5. Vector Toxicity in Rat Hippocampus

2×10^9 genome copies of JΔNI5R0ΔB, JΔNI5ΔB, or JΔNI8ΔB were injected into rat hippocampi, and brain sections were collected and processed 7 days later. (A–C) Fluoro-Jade C (FJC)-stained hippocampal sections from JΔNI-injected animals. Representative merged images of FJC staining (green), DAPI staining (blue), and mCherry fluorescence (red) are shown. (D–L) Immunohistochemical staining of brain sections for CD45 (D–F), caspase-3 (G–I), and NOS-2 (J–L) (all in green) is shown as merged images with DAPI staining (blue) and mCherry fluorescence (red). (M) Quantification of FJC, CD45, caspase-3, and NOS-2 in the hippocampus of rats 1 week after injection of JΔNI5R0ΔB, JΔNI5ΔB, or JΔNI8ΔB. Data are means \pm SEM (n = three to five animals/group, five sections/animal). *p < 0.05; **p < 0.01 (ANOVA and post hoc Kruskal-Wallis test).



observation prompted our current efforts to examine the potential of this vector and its *vhs*-deficient counterpart, JΔNI8, for CNS applications. The results indicated that both vectors are safe in the brain and express their transgene at detectable levels from the ICP4 locus for at least 1 month but also that JΔNI8 provides the more robust expression profile of the two.

Vhs plays a key role in attenuating the host anti-viral response by mediating mRNA degradation and inhibiting host protein synthesis. After virus entry into the cell through membrane fusion, vhs present in the virion tegument is released into the cytoplasm where it causes the shutoff of host protein synthesis. Available evidence suggests that vhs-induced host shutoff action contributes to the regulation of viral gene expression, in part by removing competition with cellular mRNAs for translation factors and sharpening the transition between the kinetic classes of viral genes, thereby supporting efficient virus replication during the lytic cycle.^{19–21} However, the functional significance of vhs in cell culture appears to vary between host cells. For example, U2OS cells were reported to be permissive for replication of viruses carrying a 588-nt deletion in the *vhs* gene²⁶; these are the parental cells used to generate the U2OS-ICP4/27 cells in which we propagate our JΔNI viruses, and indeed we observed little difference in the growth rates of JΔNI5 and JΔNI8 in these cells (Figure 1B). In other reports, a nonsense mutant of *vhs*, UL41NHB, showed a growth delay in mouse embryonic fibroblasts²⁷ but grew normally in Vero and C3H10T1/2 mouse embryo cells,²⁸ while a *vhs* mutant that contained a *lacZ* gene insertion in the vhs open reading frame (ORF) exhibited a severe growth defect in human fibrosarcoma HT1080 cells.²⁹ It has further been shown that vhs enhances the accumulation of viral late gene products in HeLa cells but is dispensable for late gene product accumulation in Vero and other permissive cells.²⁶ In a similar vein, while treatment of human embryonic fibroblasts with IFN- α or - β significantly inhibited plaque formation by a *vhs*-deficient mutant,³⁰ IFN- α treatment did not reduce the plaquing efficiency of a *vhs* mutant on Vero and U2OS cells.³¹ These observations clearly showed that the role of vhs is variable between cell types and indicated that vhs function is not critical in certain cell types. The host-cell-dependent mechanism of vhs action is further supported by evidence that primary sympathetic and sensory neuronal cultures are resistant to vhs-mediated shut off of protein synthesis,³² an effect that could be overcome by increasing the multiplicity of infection (MOI) and therefore the amount of vhs delivered to the cell during infection.²¹

The effect of *vhs* deletion has typically been assessed in vectors that still retained expression of ICP0. The ICP0 protein globally stimulates the expression of HSV genes, thereby enabling the production of viral gene products that may act to compensate for vhs deficiency, including ICP0 itself. ICP0 also has E3 ubiquitin ligase activity targeting the degradation of host-cell proteins involved in the antiviral response, some of which are also targets of vhs-mediated mRNA degradation.^{33,34} Thus, any effects of *vhs* disruption may be masked by effects of ICP0. The *vhs* gene has been a favored target in replication-defective HSV vectors for replacement or insertion of therapeutic transgene cassettes because *vhs* is dispensable in Vero cells typically used for HSV

growth.³⁵ These vectors generally also expressed ICP0, potentially obscuring any remaining effects of *vhs* disruption. Using a vector that is deficient in all IE gene activity, our study reveals an unexpected consequence of deletion of the entire *vhs* ORF. While virus growth in complementing U2OS-ICP4/27 cells, transduction efficiency of fibroblasts, viral gene expression in fibroblasts, and toxicity for sensory neurons in culture and hippocampal neurons in vivo were largely unaffected by the deletion, reporter gene expression from the UbC promoter in a deleted ICP4 locus was specifically enhanced in neurons. In vivo, expression persisted at an elevated level for at least 1 month.

Both the cellular promoter and genomic location are of interest when considering our results. The UbC promoter has been tested for transgene expression both in lentivirally transduced cultured neurons in vitro and in transgenic mouse lines in vivo, revealing that it is active and drives consistent levels of transgene expression in neuronal cells.^{36,37} With respect to the location of the transgene in the HSV genome, a recent report by Harkness et al. evaluating global HSV genome expression in non-neuronal MRC5 cells and trigeminal ganglion (TG) neurons infected with an IE gene-deficient HSV mutant, *d109*, made several observations of note. *d109* was generally more transcriptionally active in TG neurons than in MRC5 cells (approximately 10-fold), and, in particular, the expression of LAT and other genes within, or adjacent to, the terminal/internal repeat regions was enhanced compared to the remainder of the genome in neurons.³⁸ These findings are consistent with our observations that both JΔNI5 and JΔNI8 showed enhanced expression specifically in DRGs, but not in HDFs, of the UbC-promoter driven mCherry construct that is positioned at the deleted ICP4 locus in the terminal repeat region of the genome. Our findings indicate that additional deletion of *vhs* from the viral genome may further enhance the transcriptional activity of this genomic location in neuronal cells. While other repeat-associated genes were also expressed at higher levels in DRGs than in HDFs, and than genes within the unique regions of the viral genome in DRGs, *vhs* deletion did not further increase their expression ($\gamma_134.5$) and in fact reduced ICP22 mRNA abundance. The effect of *vhs* removal on transgene expression from the terminal repeat-based LAT locus was also not dramatic. Expression in neurons was modestly enhanced by *vhs* deletion, but this effect was not as robust, nor was it maintained as long as at the ICP4 locus. In HDFs, *vhs* removal led to reduced reporter gene expression from the LAT locus and the already low levels of viral mRNAs appeared to trend toward further reduction. Together, these observations suggest distinctly separate utilities for the JΔNI5 and JΔNI8 vectors with respect to the target cell for transgene expression; the ICP4 locus of JΔNI8 is favored for expression in neurons, while the LAT locus of JΔNI5 is preferable for expression in non-neuronal cell types.

The key event differentiating between JΔNI5 and JΔNI8 infection would appear to be the initial introduction of vhs protein into non-complementing cells as a component of the JΔNI5 virion as (1) vhs protein is synthesized and incorporated into infectious particles during JΔNI5, but not JΔNI8 virus production by ICP4/ICP27-complementing U2OS cells, and (2) de novo expression of viral genes is

extremely low in neurons infected with our vectors. However, we observed expression differences between the two vectors out to at least 14 days in vitro and 1 month in vivo, long after the vhs protein is degraded. As the incoming HSV genome is not epigenetically modified and its subsequent silencing is controlled by cellular and viral factors upon entry into the host cell,³⁹ it is conceivable that the initial exposure of JΔNI5-infected neurons to vhs indirectly affects the epigenetic status of the mCherry locus, causing persistent downregulation of the gene. While further studies are required to test this and other possibilities, our current results indicate that vhs deletion may be an attractive feature for highly defective HSV gene therapy vectors for nervous system disorders.

MATERIALS AND METHODS

Cells

HDFs (PCS-201-010; ATCC) were cultured in DMEM (Lonza) with 10% (v/v) fetal bovine serum (FBS; Sigma) and penicillin-streptomycin (P/S). Vero-based ICP4/ICP27-complementing 7b cells (Vero-7b)⁴⁰ were cultured in DMEM with 5% FBS and P/S. Primary fetal rDRGs were isolated and cultured as described previously.¹⁸ U2OS-ICP4/27 cells were grown in DMEM with 10% FBS and P/S in the presence of puromycin (2 μg/mL) and blasticidin (10 μg/mL), and U2OS-ICP4/27/Cre cells were maintained in DMEM with 10% FBS and P/S in the presence of puromycin, blasticidin, and hygromycin (200 μg/mL), as described previously.¹⁸

HSV-BAC Engineering

All BAC engineering was performed in *E. coli* strain GS1783⁴¹ as described.¹⁸ JΔNI8 and JΔNI8GFP BAC constructs were derived, respectively, from JΔNI5 and JΔNI7GFP BACs.¹⁸ To delete the vhs (U₁41) coding sequence (GenBank JQ673480, positions 91,088–92,557), the kanamycin selection marker, I-*SceI-aphAI*, was amplified from pEPkan-S2 by PCR with primers 5'-tatcaattgtgctgtgttg tggaaaagcaccagctggatgatgtgtacacgcgcgaaggatgacgacgataagtagggata-3' and 5'-aatctgcagggcgccctacaaccaattaaccaattctgattag-3'. The PCR product was gel-purified and recombined with the vhs gene of JΔNI5 BAC or JΔNI7GFP BAC, followed by removal of the *aphAI* gene.

JΔNI5R0 was constructed as follows: KOS-BAC DNA⁴² was digested with *DraI* and *PsiI* to isolate a fragment containing the complete ICP0 gene. The ICP0 fragment was cloned into the pCR-Blunt vector using the Zero Blunt PCR cloning kit (Thermo Fisher Scientific), creating pCRBlunt-ICP0. The I-*SceI-aphAI* fragment was amplified by PCR with primers (5'-tatcaattgcgcaacacctgcccgtgtgcaacccaagctggtgtactgtagtgggaggatgacgacgataagtagggata-3' and 5'-aatctgcagcaattgctacaaccaattaaccaattctgattag-3'), and the product was inserted into the *MfeI* site of pCRBlunt-ICP0, creating pCRBlunt-ICP0-KAN. The pCRBlunt-ICP0-KAN plasmid was digested with *EcoRI* and *PstI*, and the isolated ICP0-KAN fragment was used for recombination with JΔNI5 BAC DNA. All HSV-BAC modifications were confirmed by field inversion gel electrophoresis (FIGE) analysis of restriction enzyme digests (FIGE mapper; Bio-Rad), PCR analysis, and targeted DNA sequencing.

Viruses

Production of infectious virus from BAC recombinants, Cre-mediated BAC excision, and virus titration were performed as described previously.¹⁸ JΔNI viruses were grown in U2OS-ICP4/27 cells, the KOS virus stock was produced on Vero cells, and QOZH virus¹² was grown in Vero-7b cells.

Virus Growth Curves

Duplicate wells of 4×10^5 U2OS-ICP4/27 cells were infected with JΔNI viruses at 1 gc/cell for 2 hr at 37°C, treated with 0.1 M glycine (pH 3.0) for 1 min to inactivate extracellular virus, and incubated at 37°C and 5% CO₂. The supernatants were collected daily for viral DNA extraction and titration by qPCR for the gD gene, as described.¹⁸

Cytotoxicity Assay

Cell viability was measured essentially as described.⁴³ Briefly, dissociated rDRGs were plated in a 24-well plate (9×10^4 cells/well) and infected with KOS or JΔNI viruses at 3,000 gc/cell. Cell viability was determined 5 days later by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.

qRT-PCR and Genomic qPCR

HDF and rDRG cells were plated in 24-well plates, and duplicate wells were infected 24 hr later with JΔNI viruses at MOIs of 25,000 gc/cell or 3,000 gc/cell, respectively. Total RNA was extracted, and RT was carried out by Cells-to-cDNA II Kit (Ambion). Real-time PCR for each sample was performed in triplicate using the StepOnePlus Real-Time PCR System (Applied Biosystems). The data were normalized to viral gc in the same samples determined by qPCR for the gD gene or (Figure 2D) using separate JΔNI5 BAC DNA standard curves generated for each gene with the gene-specific primer pairs used for cDNA qPCR to allow for mRNA/gc comparisons between genes and across host cells. All primers for qPCR were as previously reported.¹⁸ The gc titers of virus stocks and nuclear viral DNA copy numbers were determined as described.¹⁸

In Vivo Experiments

Under ketamine (90 mg/kg i.p.) and xylazine (13 mg/kg i.p.) anesthesia, 2×10^9 gc of JΔNI vectors were inoculated into the right dorsal hippocampus of male rats (Harlan Sprague Dawley, 300 g). The viral vectors (JΔNI5R0, JΔNI5, and JΔNI8) were injected by stereotactic implantation of a borosilicate glass needle linked to a microperfusion pump in a volume of 3 μL at a flow rate of 200 nL/min. In order to facilitate the needle entry into the brain tissue and to reduce the mechanical damage, the needle tip had been laser-chamfered (inner diameter at tip = 60 μm) using Leica Laser Microdissector CTR6000 (Leica Microsystems). The stereotactic coordinates for the hippocampal inoculation, based on the Paxinos atlas,⁴⁴ were 2.1 mm lateral and 3 mm posterior to bregma, 3.5 mm deep from dura. Experiments were performed at the University of Ferrara in compliance with the university's guidelines for the ethical treatment of experimental animals.

Tissue Preparation

Animals were anesthetized with pentobarbital at 7 or 30 days post-virus injection and perfused with 0.1 M PBS followed by 4% paraformaldehyde. The brains were quickly removed and post-fixed in 4% paraformaldehyde for 1 hr, cryoprotected in 30% sucrose at 4°C until the tissue sank, and snap frozen in isopentane at –80°C.

Immunofluorescence

20- μ m coronal cryostat sections were cut at –20°C on a freezing microtome, rinsed in 0.1 M PBS for free-floating immunostaining, and blocked with 10% normal goat serum/0.3% Triton X-100. Sections were then incubated overnight at 4°C with primary antibodies dissolved in blocking solution as follows: CD45 (Santa Cruz Biotechnology, sc-53047), 1:100; cleaved caspase-3 (Cell Signaling Technology, 9664), 1:100; nitric oxide synthase-2 (Santa Cruz, sc-651), 1:100; mCherry (Thermo Fisher Scientific), 1:100; GFAP (Sigma), 1:200; O4 (Sigma), 1:100. After washing in PBS, sections were incubated in blocking solution with 10 μ M DAPI (Molecular Probes, D3571) and either Alexa Fluor 488 goat anti-rabbit (Molecular Probes, A11008, 1:1,000) or Alexa Fluor 488 goat anti-mouse (Molecular Probes, A11029, 1:1,000) for 1 hr at room temperature.

Fluoro-Jade C Staining

Brain sections were mounted on frosted microscope slides (Thermo Fisher Scientific) and pretreated for 5 min in 80% EtOH/1% NaOH, 2 min in 70% EtOH, and 2 min in distilled water. Sections were then incubated for 10 min in a 0.06% KMnO₄ solution and rinsed in distilled water for 3 min before incubation in a 0.0001% solution of Fluoro-Jade C (Immunological Sciences, IS-0012) in 0.1% acetic acid for 10 min. After three washes in distilled water for 1 min, slides were dried, dehydrated with xylene, and coverslipped with DPX mountant (Sigma) for microscopy.

Hippocampal Image Quantifications

Brain sections were imaged using a DMRA2 Leica microscope (Leica Microsystems) and Hamamatsu C11440 camera. Confocal images were captured using a HAL 100 camera (Zeiss) mounted on a Zeiss LSM510 confocal microscope. Imaged mCherry expression was quantified with MetaMorph (Universal Imaging). The entire hippocampus was selected as the region of interest (ROI). mCherry-positive pixels were identified by thresholding at the gray level corresponding to the mean plus the difference between average and minimum. Using this approach, only those pixels that were significantly above background (i.e., mCherry-positive) were selected. The percentage of mCherry-positive pixels in the hippocampus was calculated as the ratio of pixels above threshold to total pixels in the ROI.

A similar procedure was employed for quantification of FJC, CD45, caspase-3, and NOS-2 signals. An outline was drawn around five positive cells, and mean gray values were measured and averaged; the resulting value was used to set the image threshold. Pixels above the threshold were identified, as described above, and the number of positive pixels was expressed as the percentage of total pixels.

For each injected animal, the number of mCherry-, FJC-, CD45-, caspase-3-, and NOS-2-positive pixels was quantified from five regularly interspaced sections spanning across the injection site (one of every five 20- μ m sections cut across the injection site, i.e., one per 100 μ m with the third at the site of injection), and the average per animal (three to five animals/group) was determined. These averages were used for statistical analysis.

Statistical Analyses

Data from in vitro experiments are presented as the mean \pm SD. Data from in vivo experiments were analyzed by the Kruskal-Wallis test to determine significance.

SUPPLEMENTAL INFORMATION

Supplemental Information includes four figures and can be found with this article online at <http://dx.doi.org/10.1016/j.omtm.2017.06.001>.

AUTHOR CONTRIBUTIONS

Conceptualization, Y.M.; Investigation, Y.M., G.V., F.H., H.U., S.Z., and W.F.G.; Formal Analysis, Y.M., G.V., B.R., M.S., J.B.C., and J.C.G.; Supervision, M.S., J.B.C., and J.C.G.; Writing – Original Draft, Y.M.; Writing – Review & Editing, B.R., J.B.C., and J.C.G.; Funding Acquisition, W.F.G., M.S., J.B.C., and J.C.G.

CONFLICTS OF INTEREST

G.V., M.S., and J.C.G. are founders of NuvoVec srl. Y.M., J.B.C., and J.C.G. are co-inventors of intellectual property licensed to SwitchBio, Inc. H.U., J.B.C., and J.C.G. are co-inventors of intellectual property licensed to Oncorus, Inc. J.C.G. is a founder and consultant of SwitchBio, Inc. and Oncorus, Inc. B.R. and W.F.G. are consultants of Oncorus, Inc.

ACKNOWLEDGMENTS

We are grateful to Klaus Osterrieder (Free University of Berlin, Germany) for plasmid pEPkan-S2, Greg Smith (Northwestern University) for *E. coli* strain GS1783, David Leib (Dartmouth Medical School) for KOS-37 BAC DNA, Mingdi Zhang for rat DRG cultures, and Jim Smiley (University of Alberta, Canada) for helpful comments on the manuscript. This work was supported by grants to J.C.G. from the NIH (NS064988 and DK044935), the CHDI Foundation (A3777 and A8790), and the Commonwealth of Pennsylvania (SAP #4100061184) and to M.S. from the European Community (FP7-PEOPLE-2011-IAPP project 285827 [EPIXCHANGE]) and the Italian Ministry for Education, University and Research (PRIN project 2010N8PBAA [INBDNF]).

REFERENCES

1. Puskovic, V., Wolfe, D., Goss, J., Huang, S., Mata, M., Glorioso, J.C., and Fink, D.J. (2004). Prolonged biologically active transgene expression driven by HSV LAP2 in brain in vivo. *Mol. Ther.* 10, 67–75.
2. Smith, C., Lachmann, R.H., and Efstathiou, S. (2000). Expression from the herpes simplex virus type 1 latency-associated promoter in the murine central nervous system. *J. Gen. Virol.* 81, 649–662.

3. Zhu, J., Kang, W., Wolfe, J.H., and Fraser, N.W. (2000). Significantly increased expression of beta-glucuronidase in the central nervous system of mucopolysaccharidosis type VII mice from the latency-associated transcript promoter in a nonpathogenic herpes simplex virus type 1 vector. *Mol. Ther.* 2, 82–94.
4. Palmer, J.A., Branston, R.H., Lilley, C.E., Robinson, M.J., Groutsi, F., Smith, J., Latchman, D.S., and Coffin, R.S. (2000). Development and optimization of herpes simplex virus vectors for multiple long-term gene delivery to the peripheral nervous system. *J. Virol.* 74, 5604–5618.
5. Perez, M.C., Hunt, S.P., Coffin, R.S., and Palmer, J.A. (2004). Comparative analysis of genomic HSV vectors for gene delivery to motor neurons following peripheral inoculation in vivo. *Gene Ther.* 11, 1023–1032.
6. Goss, J.R., Cascio, M., Goins, W.F., Huang, S., Krisky, D.M., Clarke, R.J., Johnson, J.W., Yokoyama, H., Yoshimura, N., Gold, M., et al. (2011). HSV delivery of a ligand-regulated endogenous ion channel gene to sensory neurons results in pain control following channel activation. *Mol. Ther.* 19, 500–506.
7. Goss, J.R., Mata, M., Goins, W.F., Wu, H.H., Glorioso, J.C., and Fink, D.J. (2001). Antinociceptive effect of a genomic herpes simplex virus-based vector expressing human proenkephalin in rat dorsal root ganglion. *Gene Ther.* 8, 551–556.
8. McMenamin, M.M., Byrnes, A.P., Charlton, H.M., Coffin, R.S., Latchman, D.S., and Wood, M.J. (1998). A gamma34.5 mutant of herpes simplex 1 causes severe inflammation in the brain. *Neuroscience* 83, 1225–1237.
9. Scarpini, C.G., May, J., Lachmann, R.H., Preston, C.M., Dunnett, S.B., Torres, E.M., and Efstathiou, S. (2001). Latency associated promoter transgene expression in the central nervous system after stereotaxic delivery of replication-defective HSV-1-based vectors. *Gene Ther.* 8, 1057–1071.
10. Bloom, D.C., Maidment, N.T., Tan, A., Dissette, V.B., Feldman, L.T., and Stevens, J.G. (1995). Long-term expression of a reporter gene from latent herpes simplex virus in the rat hippocampus. *Brain Res. Mol. Brain Res.* 31, 48–60.
11. Boutell, C., and Everett, R.D. (2013). Regulation of alphaherpesvirus infections by the ICP0 family of proteins. *J. Gen. Virol.* 94, 465–481.
12. Chen, X., Li, J., Mata, M., Goss, J., Wolfe, D., Glorioso, J.C., and Fink, D.J. (2000). Herpes simplex virus type 1 ICP0 protein does not accumulate in the nucleus of primary neurons in culture. *J. Virol.* 74, 10132–10141.
13. Goins, W.F., Lee, K.A., Cavalcoli, J.D., O'Malley, M.E., DeKosky, S.T., Fink, D.J., and Glorioso, J.C. (1999). Herpes simplex virus type 1 vector-mediated expression of nerve growth factor protects dorsal root ganglion neurons from peroxide toxicity. *J. Virol.* 73, 519–532.
14. Chattopadhyay, M., Wolfe, D., Mata, M., Huang, S., Glorioso, J.C., and Fink, D.J. (2005). Long-term neuroprotection achieved with latency-associated promoter-driven herpes simplex virus gene transfer to the peripheral nervous system. *Mol. Ther.* 12, 307–313.
15. Margolis, T.P., Bloom, D.C., Dobson, A.T., Feldman, L.T., and Stevens, J.G. (1993). Decreased reporter gene expression during latent infection with HSV LAT promoter constructs. *Virology* 197, 585–592.
16. Labetoulle, M., Mailet, S., Efstathiou, S., Dezelee, S., Frau, E., and Lafay, F. (2003). HSV1 latency sites after inoculation in the lip: Assessment of their localization and connections to the eye. *Invest. Ophthalmol. Vis. Sci.* 44, 217–225.
17. Amelio, A.L., McAnany, P.K., and Bloom, D.C. (2006). A chromatin insulator-like element in the herpes simplex virus type 1 latency-associated transcript region binds CCCTC-binding factor and displays enhancer-blocking and silencing activities. *J. Virol.* 80, 2358–2368.
18. Miyagawa, Y., Marino, P., Verlengia, G., Uchida, H., Goins, W.F., Yokota, S., Geller, D.A., Yoshida, O., Mester, J., Cohen, J.B., et al. (2015). Herpes simplex viral-vector design for efficient transduction of nonneuronal cells without cytotoxicity. *Proc. Natl. Acad. Sci. USA* 112, E1632–E1641.
19. Rivas, H.G., Schmalings, S.K., and Gaglia, M.M. (2016). Shutoff of host gene expression in influenza A virus and herpesviruses: Similar mechanisms and common themes. *Viruses* 8, 102.
20. Smiley, J.R. (2004). Herpes simplex virus virion host shutoff protein: Immune evasion mediated by a viral RNase? *J. Virol.* 78, 1063–1068.
21. Strand, S.S., Vanheyningen, T.K., and Leib, D.A. (2004). The virion host shutoff protein of herpes simplex virus type 1 has RNA degradation activity in primary neurons. *J. Virol.* 78, 8400–8403.
22. Ferenczy, M.W., and DeLuca, N.A. (2009). Epigenetic modulation of gene expression from quiescent herpes simplex virus genomes. *J. Virol.* 83, 8514–8524.
23. Hobbs, W.E., Brough, D.E., Kovessi, I., and DeLuca, N.A. (2001). Efficient activation of viral genomes by levels of herpes simplex virus ICP0 insufficient to affect cellular gene expression or cell survival. *J. Virol.* 75, 3391–3403.
24. Glorioso, J.C., and Fink, D.J. (2009). Herpes vector-mediated gene transfer in the treatment of chronic pain. *Mol. Ther.* 17, 13–18.
25. Samaniego, L.A., Neiderhiser, L., and DeLuca, N.A. (1998). Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins. *J. Virol.* 72, 3307–3320.
26. Dauber, B., Pelletier, J., and Smiley, J.R. (2011). The herpes simplex virus 1 vhs protein enhances translation of viral true late mRNAs and virus production in a cell type-dependent manner. *J. Virol.* 85, 5363–5373.
27. Pasiaka, T.J., Lu, B., Crosby, S.D., Wylie, K.M., Morrison, L.A., Alexander, D.E., Menachery, V.D., and Leib, D.A. (2008). Herpes simplex virus virion host shutoff attenuates establishment of the antiviral state. *J. Virol.* 82, 5527–5535.
28. Strelow, L.I., and Leib, D.A. (1995). Role of the virion host shutoff (vhs) of herpes simplex virus type 1 in latency and pathogenesis. *J. Virol.* 69, 6779–6786.
29. Sciortino, M.T., Parisi, T., Siracusano, G., Mastino, A., Taddeo, B., and Roizman, B. (2013). The virion host shutoff RNase plays a key role in blocking the activation of protein kinase R in cells infected with herpes simplex virus 1. *J. Virol.* 87, 3271–3276.
30. Suzutani, T., Nagamine, M., Shibaki, T., Ogasawara, M., Yoshida, I., Daikoku, T., Nishiyama, Y., and Azuma, M. (2000). The role of the UL41 gene of herpes simplex virus type 1 in evasion of non-specific host defence mechanisms during primary infection. *J. Gen. Virol.* 81, 1763–1771.
31. Mossman, K.L., Saffran, H.A., and Smiley, J.R. (2000). Herpes simplex virus ICP0 mutants are hypersensitive to interferon. *J. Virol.* 74, 2052–2056.
32. Nichol, P.F., Chang, J.Y., Johnson, E.M., Jr., and Olivo, P.D. (1994). Infection of sympathetic and sensory neurones with herpes simplex virus does not elicit a shut-off of cellular protein synthesis: Implications for viral latency and herpes vectors. *Neurobiol. Dis.* 1, 83–94.
33. Lin, R., Noyce, R.S., Collins, S.E., Everett, R.D., and Mossman, K.L. (2004). The herpes simplex virus ICP0 RING finger domain inhibits IRF3- and IRF7-mediated activation of interferon-stimulated genes. *J. Virol.* 78, 1675–1684.
34. Orzalli, M.H., Broekema, N.M., and Knipe, D.M. (2016). Relative contributions of herpes simplex virus 1 ICP0 and vhs to loss of cellular IFI16 vary in different human cell types. *J. Virol.* 90, 8351–8359.
35. Goins, W.F., Krisky, D.M., Wechuck, J.B., Wolfe, D., Huang, S., and Glorioso, J.C. (2011). Generation of replication-competent and -defective HSV vectors. *Cold Spring Harb. Protoc.*, Published online May 1, 2011. <http://dx.doi.org/10.1101/pdb.prot5615>.
36. Li, M., Husic, N., Lin, Y., Christensen, H., Malik, I., McIver, S., LaPash Daniels, C.M., Harris, D.A., Kotzbauer, P.T., Goldberg, M.P., et al. (2010). Optimal promoter usage for lentiviral vector-mediated transduction of cultured central nervous system cells. *J. Neurosci. Methods* 189, 56–64.
37. Wilhelm, F., Winkler, U., Morawski, M., Jager, C., Reinecke, L., Rossner, M.J., Hirrlinger, P.G., and Hirrlinger, J. (2011). The human ubiquitin C promoter drives selective expression in principal neurons in the brain of a transgenic mouse line. *Neurochem. Int.* 59, 976–980.
38. Harkness, J.M., Kader, M., and DeLuca, N.A. (2014). Transcription of the herpes simplex virus 1 genome during productive and quiescent infection of neuronal and nonneuronal cells. *J. Virol.* 88, 6847–6861.
39. Knipe, D.M. (2015). Nuclear sensing of viral DNA, epigenetic regulation of herpes simplex virus infection, and innate immunity. *Virology* 479–480, 153–159.
40. Krisky, D.M., Wolfe, D., Goins, W.F., Marconi, P.C., Ramakrishnan, R., Mata, M., Rouse, R.J., Fink, D.J., and Glorioso, J.C. (1998). Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons. *Gene Ther.* 5, 1593–1603.

41. Tischer, B.K., Smith, G.A., and Osterrieder, N. (2010). En passant mutagenesis: A two step markerless red recombination system. *Methods Mol. Biol.* 634, 421–430.
42. Gierasch, W.W., Zimmerman, D.L., Ward, S.L., Vanheyningen, T.K., Romine, J.D., and Leib, D.A. (2006). Construction and characterization of bacterial artificial chromosomes containing HSV-1 strains 17 and KOS. *J. Virol. Methods* 135, 197–206.
43. Uchida, H., Marzulli, M., Nakano, K., Goins, W.F., Chan, J., Hong, C.S., Mazzacurati, L., Yoo, J.Y., Haseley, A., Nakashima, H., et al. (2013). Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus. *Mol. Ther.* 21, 561–569.
44. Paxinos, G., and Watson, C. (1982). *The Rat Brain in Stereotaxic Coordinates* (Academic Press).
45. Uchida, H., Chan, J., Goins, W.F., Grandi, P., Kumagai, I., Cohen, J.B., and Glorioso, J.C. (2010). A double mutation in glycoprotein gB compensates for ineffective gD-dependent initiation of herpes simplex virus type 1 infection. *J. Virol.* 84, 12200–12209.
46. Berthomme, H., Thomas, J., Texier, P., Epstein, A., and Feldman, L.T. (2001). Enhancer and long-term expression functions of herpes simplex virus type 1 latency-associated promoter are both located in the same region. *J. Virol.* 75, 4386–4393.
47. Goins, W.F., Sternberg, L.R., Croen, K.D., Krause, P.R., Hendricks, R.L., Fink, D.J., Straus, S.E., Levine, M., and Glorioso, J.C. (1994). A novel latency-active promoter is contained within the herpes simplex virus type 1 UL flanking repeats. *J. Virol.* 68, 2239–2252.